Literature DB >> 27297911

von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia.

Georgios N Kalambokis1, Aikaterini Oikonomou2, Leonidas Christou3, Nikolaos I Kolaitis2, Epameinondas V Tsianos4, Dimitrios Christodoulou5, Gerasimos Baltayiannis5.   

Abstract

BACKGROUND & AIMS: Several lines of evidence suggest that the hemostatic disorders of cirrhosis may have a significant clinical impact. We investigated the independent predictive value of components of the hemostatic system on the occurrence of ascites, variceal bleeding (VB), and survival.
METHODS: One hundred and two patients with thrombocytopenia (Child-Pugh class A/B/C: 34/34/34) were enrolled. Platelet counts, factors (F) II, V, VII, and VIII, antithrombin, protein C (PC), FVIII-to-PC ratio as an index of procoagulant imbalance, von Willebrand factor antigen (vWF-Ag), and model for end-stage liver disease (MELD) were evaluated. Two multivariate analyses were performed: one excluding (model 1) and one including MELD (model 2).
RESULTS: Higher vWF-Ag levels and FVIII-to-PC ratios were the most prominent hemostatic disorders in patients with cirrhosis. Increased levels of vWF-Ag and FVIII, and higher FVIII-to-PC ratios independently predicted the presence of ascites and varices at baseline. Independent predictors of ascites and VB during follow-up were vWF-Ag (model 1/2: p=0.001/p=0.009 and p=0.008/p=0.01, respectively) and FVIII-to-PC ratio (model 1/2: p=0.003/p=0.02 and p=0.01/p=0.03, respectively). vWF-Ag (model 1/2: p=0.007/p=0.002), FVIII-to-PC ratio (model 1/2: p=0.001/p=0.01), and MELD (p=0.02) independently predicted mortality. Patient groups with significantly higher probability of new-onset ascites, VB, and mortality were identified by certain cut-offs of vWF-Ag (213%, 466%, and 321%, respectively) and FVIII-to-PC ratio (1.99, 3.29, and 2.36, respectively). vWF-Ag and FVIII-to-PC ratio equaled MELD in mortality prediction.
CONCLUSIONS: Advanced cirrhosis is characterized by increased thrombotic potential. vWF-Ag and FVIII-to-PC ratio independently predict new-onset ascites, VB, and mortality. Targeting hypercoagulability could improve the outcome of patients with cirrhosis. LAY
SUMMARY: Higher von Willebrand factor antigen (vWF-Ag) levels and factor VIII-to-protein C (FVIII-to-PC) ratio are the prominent hemostatic disorders in patients with cirrhosis. vWF-Ag and FVIII-to-PC ratio independently predict new-onset ascites, variceal bleeding, and mortality in these patients.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Decompensation; Mortality; Procoagulant imbalance; von Willebrand factor antigen

Mesh:

Substances:

Year:  2016        PMID: 27297911     DOI: 10.1016/j.jhep.2016.06.002

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  19 in total

1.  Von Willebrand factor deficiency reduces liver fibrosis in mice.

Authors:  Nikita Joshi; Anna K Kopec; Jessica L Ray; Holly Cline-Fedewa; Dafna J Groeneveld; Ton Lisman; James P Luyendyk
Journal:  Toxicol Appl Pharmacol       Date:  2017-05-17       Impact factor: 4.219

Review 2.  Algorithms for managing coagulation disorders in liver disease.

Authors:  R Todd Stravitz
Journal:  Hepatol Int       Date:  2018-07-31       Impact factor: 6.047

3.  Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study.

Authors:  S Basili; V Raparelli; L Napoleone; G Talerico; G R Corazza; F Perticone; D Sacerdoti; A Andriulli; A Licata; A Pietrangelo; A Picardi; G Raimondo; F Violi
Journal:  Am J Gastroenterol       Date:  2017-12-19       Impact factor: 10.864

Review 4.  Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?

Authors:  Dafna J Groeneveld; Lauren G Poole; James P Luyendyk
Journal:  J Thromb Haemost       Date:  2021-05-03       Impact factor: 16.036

5.  Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis.

Authors:  Michał Kukla; Marek Waluga; Michał Żorniak; Agnieszka Berdowska; Piotr Wosiewicz; Tomasz Sawczyn; Rafał J Bułdak; Marek Ochman; Katarzyna Ziora; Tadeusz Krzemiński; Marek Hartleb
Journal:  World J Gastroenterol       Date:  2017-04-14       Impact factor: 5.742

6.  Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.

Authors:  Maxime G Zermatten; Montserrat Fraga; Debora Bertaggia Calderara; Alessandro Aliotta; Darius Moradpour; Lorenzo Alberio
Journal:  JHEP Rep       Date:  2020-05-11

7.  Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference.

Authors:  N M Intagliata; C K Argo; J G Stine; T Lisman; S H Caldwell; F Violi
Journal:  Thromb Haemost       Date:  2018-07-30       Impact factor: 5.249

8.  Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation.

Authors:  Eszter Palyu; Jolan Harsfalvi; Tamas Tornai; Maria Papp; Miklos Udvardy; Katalin Szekeres-Csiki; Lajos Pataki; Karen Vanhoorelbeke; Hendrik B Feys; Hans Deckmyn; Istvan Tornai
Journal:  Thromb Haemost       Date:  2018-07-04       Impact factor: 5.249

9.  Assessment of hemostatic profile in patients with mild to advanced liver cirrhosis.

Authors:  Elisabeth Hannah Adam; Madara Möhlmann; Eva Herrmann; Sonia Schneider; Kai Zacharowski; Stefan Zeuzem; Christian Friedrich Weber; Nina Weiler
Journal:  World J Gastroenterol       Date:  2020-05-07       Impact factor: 5.742

Review 10.  Coagulation, Microenvironment and Liver Fibrosis.

Authors:  Niccolò Bitto; Eleonora Liguori; Vincenzo La Mura
Journal:  Cells       Date:  2018-07-24       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.